In Germany, for example, the Federal Joint Committee (G-BA) has limited PCSK9-mAb reimbursement to a specific subset of ASCVD patients who do not achieve LDL-C targets despite optimal oral lipid-lowering therapies [7, 8]. This evidence concerns the gene PCSK9 and atherosclerosis.